ReviewAdvances in experimental medicine and biology2022
Influenza Virus Entry inhibitors.
Review in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Deoxyshikonin Inhibits Influenza A Virus Infection at an Early Stage.International journal of molecular sciences · 2025Article
- Nasal Emulgel's Role in Preventing Coronavirus Infection.Pharmaceutics · 2025Article
- Cilnidipine exerts antiviral effects in vitro and in vivo by inhibiting the internalization and fusion of influenza A virus.BMC medicine · 2025Article
- Antiviral Activity of Berbamine Against Influenza A Virus Infection.International journal of molecular sciences · 2025Article
- The therapeutic potential of thiocyanate and hypothiocyanous acid against pulmonary infections.Free radical biology & medicine · 2024Review
- Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein.Signal transduction and targeted therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is a major challenge to health and the global economy. However, the increasing emergence of drug resistance during influenza pandemics cannot be ignored. It is particularly important to design and develop anti-influenza drugs with novel mechanisms of action for the treatment and prevention of influenza virus infections. Virus entry is the first essential step in the viral life cycle, the prevention of which leads to suppression of viral infectivity and is an attractive antiviral strategy. Here, we review the development of influenza entry inhibitors and their performance in clinical trials, including small molecule, natural product, peptide-based entry inhibitors, and other types of entry inhibitors, herein discussing some open questions. Assay methods of influenza virus entry inhibitors are also outlined.
Indexed as
Identifiers
35412138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.